Run time: 79m

  0       0

2018 Annual Meeting On-Demand


2018 AM On-Demand: Session ST2-13-SS-2018: Seven-Day Platelets: Quality Implications, Safety Benefits, and Implementation Challenges


Oct 19, 2018 10:00am ‐ Oct 19, 2018 11:30am

Expiration Date: Dec 31, 2020


Credits: None available.

Description

This program is available until December 31, 2020.

Program Chair: Sandra Ramirez-Arcos, MSc, PhD
Speakers: Peter Schubert; Dirk de Korte; Michael Jacobs; Ralph Vassallo, MD
Intended Audience: Technologist, Student (MD, MT, SBB), Residents/Fellow, Transfusion Safety Officer, Research Scientist, Physician, Medical Director
Teaching Level: Intermediate

Learning Objectives:

  • Compare in vitro quality of 5-day and 7-day platelets
  • Review clinical outcomes of transfusing 5-day and 7-day platelets
  • Discuss the impact of extending platelet shelf-life to 7 days on patient safety
  • Analyze the challenges posed to blood suppliers and blood centers with the extension of platelet shelf-life to 7 days

Description: With the advent of improved screening protocols for bacterial testing, availability of rapid testing methods, and pathogen reduction technologies, extending the shelf life of platelets to seven days seems to be the right thing to do. However, these changes may pose implementation challenges for blood suppliers and blood centers. Speakers in this session will review the current knowledge on the quality of 7-day platelets and the clinical outcomes of transfusing older platelets, including pathogen-inactivated products. Discussion will also be focused on the pros and cons of implementing 7-day platelets and the different strategies available to make 7-day platelets safely available for transfusion patients.

Speaker(s):

Disclosures

  • Ralph Vassallo, MD :

    Consultant: bioMerieux, Fresenius Kabi, HemaNext, Cerus Corp  |  Terumo BCT: Speaker's Bureau

  • Peter Schubert, MSc, PhD :

    Nothing to Disclose

  • Sandra Ramirez-Arcos, MSc, PhD :

    Cerus: Invited Speaker to a Cerus-sponsored Meeting  |  bioMerieux: Invited guest speaker by bioMerieux ASPAC Industrial Microbiology to the Japanese Red Cross Symposium

  • Michael Jacobs :

    Verax: Consultant  |  Verax: Grant/Research Support (Secondary Investigators need not disclose)  |  Verax: Honoraria  |  Pall: Grant/Research Support (Secondary Investigators need not disclose)  |  Gambro: Grant/Research Support (Secondary Investigators need not disclose)  |  Hemosystem: Grant/Research Support (Secondary Investigators need not disclose)  |  Immunetics: Consultant  |  Immunetics: Grant/Research Support (Secondary Investigators need not disclose)  |  Immunetics: Honoraria  |  GenPrime: Grant/Research Support (Secondary Investigators need not disclose)  |  Fenwal: Grant/Research Support (Secondary Investigators need not disclose)  |  Charles Rivers Labs: Grant/Research Support (Secondary Investigators need not disclose)  |  bioMerieux: Grant/Research Support (Secondary Investigators need not disclose)  |  bioMerieux: Honoraria  |  BioSense Technologies: Consultant  |  Lynntech: Consultant  | Blood Systems: Consultant

  • Dirk de Korte :

    Nothing to Disclose

Credits

  • 1.25 - General Continuing Education (GEN)
  • 1.25 - Florida Lab Personnel (FLP)
  • 1.25 - California Nurse (CN)
  • 1.25 - California Lab Personnel (CLP)
  • 1.25 - Physician (PHY)

You must be logged in and own this session in order to post comments.

Print Certificate
Review Answers
Print Transcript
Completed on: token-completed_on
Review Answers
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content